98%
921
2 minutes
20
Background: Preterm birth is associated with low nephron endowment, with an increased risk of chronic kidney disease (CKD) later in life. Almost all pregnant women at risk for preterm delivery are given antenatal corticosteroids (ANS) to accelerate lung maturity in preterm neonates. Similar to ANS, postnatal corticosteroids are also given to improve lung function, but the impact on kidney function is unknown. The objective of this study was to determine if duration and timing of postnatal corticosteroids in preterm infants influences kidney function at 24 months corrected age.
Methods: A secondary analysis of the PENUT trial (neonates <28 weeks' gestation) was performed and included surviving participants with serum creatinine measured at 22-26 months corrected gestational age (cGA). Exposure included the presence, type, start date, and duration of postnatal steroids (duration and start date based on postmenstrual age (PMA)). The primary outcome was reduced estimated GFR (GFR <90 ml/min/1.73 m2 at the 24-month CGA timepoint). Outcomes were adjusted for perinatal/neonatal exposures, and neonatal outcomes were compared.
Results: Out of 838 surviving infants, 397 (47%) were exposed to any postnatal steroid. Dexamethasone was the most common exposure (n = 238, median start date at day of life (DOL) 27, median duration of 8 days), followed by hydrocortisone (n = 232, median start DOL 13, median duration 17 days). 348 infants were evaluated at 22-26-month follow-up, 61 of whom had reduced GFR. Hydrocortisone duration of 1-7 days had 2.8 (95% CI = 1.06-7.62) times increased odds of reduced GFR at 24 months corrected age. Although overall steroid exposure was not associated with GFR at follow-up, initiation of dexamethasone at ≤25 weeks PMA was associated with 9.39 (95% CI = 1.61-54.71) increased odds of reduced GFR compared to those given dexamethasone at ≥29 weeks.
Conclusions: Although observational, this study supports an association between postnatal steroid timing, duration, and reduced GFR. Further studies are warranted to better understand this association to protect long-term kidney health.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.34067/KID.0000000824 | DOI Listing |
Trop Doct
September 2025
Additional Professor, Department of Radiodiagnosis, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Chikungunya virus (CHIKV) typically causes febrile illness and arthralgia. However, severe complications such as encephalitis, rhabdomyolysis, and multiorgan dysfunction are increasingly recognised, particularly during epidemics in endemic regions. We report a case of a 61-year old male presenting with progressive flaccid paraparesis and respiratory failure following febrile illness.
View Article and Find Full Text PDFCell Mol Biol (Noisy-le-grand)
September 2025
University Sousse, Faculty of Medicine "Ibn El-Jazzar", Department of Medical Genetics, Sousse, Tunisia.
The global epidemic of overweight and obesity is closely linked to the development of chronic kidney disease (CKD), with extremely obese individuals facing a particularly high risk. This study aimed to assess the relationship between lipid profile levels, SIRT1 expression, and RNA-34a-5P in the regulation of blood lipid levels among severely obese individuals with renal diseases. Conducted over six months in three specialized hospitals, the study included 100 participants divided into two groups: 50 obese individuals with renal diseases and 50 obese controls without renal problems.
View Article and Find Full Text PDFBioDrugs
September 2025
Department of Nephrology, Instituto de Investigación Hospital "12 de Octubre" (imas12), Avda. De Córdoba s/n, 28041, Madrid, Spain.
Anti-CD20 monoclonal antibodies are gaining clinical relevance in the nephrology community due to their demonstrated efficacy and favorable safety profiles across short-, medium-, and long-term use. Initially developed for hematologic malignancies and multiple sclerosis, B-cell depletion therapies are now being investigated across a broader spectrum of autoimmune diseases, including glomerulopathies, both with and without associated podocytopathy. Recent advances have led to the development of novel anti-CD20 agents that are being used not only as potential alternatives to corticosteroids but also as adjunctive therapies in complex clinical settings.
View Article and Find Full Text PDFJ Nephrol
September 2025
Division of Gastroenterology and Nephrology, Faculty of Medicine, Tottori University, Nishi-cho 36-1, Yonago, Tottori, 683-8504, Japan.
Background: Chronic kidney disease (CKD) is a public health concern; kidney size correlates with kidney function, except in diabetic kidney disease (DKD), where the kidney enlarges, limiting morphological measurement applications in CKD management. However, cortical size changes in DKD along with CKD progression remain understudied. We investigated kidney morphology alterations in patients with and without diabetes and established a regression equation for kidney function incorporating morphological alterations.
View Article and Find Full Text PDFJ Nephrol
September 2025
Nephrology and Dialysis Unit, ASL Nord Ovest Toscana, Livorno, Italy.
Hypertension is a clinical condition associated with an increase in cardiovascular morbidity and mortality. In chronic kidney disease (CKD), hypertension is also a driver of faster disease progression. Correct and appropriate treatment with antihypertensive medication reduces the risk of cardiovascular events and slows kidney disease progression.
View Article and Find Full Text PDF